Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1036

1.

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.

Circulation. 2006 Jun 27;113(25):2906-13. Epub 2006 Jun 19.

3.

Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.

Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503.

PMID:
17086567
5.

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.

Ann Intern Med. 2005 Feb 1;142(3):157-64.

PMID:
15684203
6.

Factors associated with celecoxib and rofecoxib utilization.

Rawson NS, Nourjah P, Grosser SC, Graham DJ.

Ann Pharmacother. 2005 Apr;39(4):597-602. Epub 2005 Mar 8.

PMID:
15755796
8.

Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.

Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.

Arthritis Res Ther. 2005;7(2):R333-42. Epub 2005 Jan 17.

9.

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.

Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.

Arch Intern Med. 2005 May 9;165(9):978-84.

PMID:
15883235
10.

Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.

Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Køber L, Hansen PR, Torp-Pedersen C, Gislason GH.

Circulation. 2011 May 24;123(20):2226-35. doi: 10.1161/CIRCULATIONAHA.110.004671. Epub 2011 May 9.

12.

Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study.

Olsen AM, Fosbøl EL, Lindhardsen J, Andersson C, Folke F, Nielsen MB, Køber L, Hansen PR, Torp-Pedersen C, Gislason GH.

PLoS One. 2013;8(1):e54309. doi: 10.1371/journal.pone.0054309. Epub 2013 Jan 30.

13.
14.
16.

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.

Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES.108.805689. Epub 2009 May 5.

17.

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.

Arthritis Rheum. 2006 May;54(5):1378-89.

18.

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

Circulation. 2004 May 4;109(17):2068-73. Epub 2004 Apr 19.

20.

Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.

Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.

Pharmacotherapy. 2009 Dec;29(12):1397-407. doi: 10.1592/phco.29.12.1397.

PMID:
19947799
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk